The stock of Gamida Cell Ltd. (NASDAQ: GMDA) has been assigned a rating of “Buy” by all six of the different brokerages who are now following the company, as reported by Bloomberg Ratings. This rating is the consensus recommendation among several brokerages. Five separate analysts have all recommended that investors purchase the stock. The stock currently has an average one-year price objective of $14.17, according to the recommendations of brokers who have reported on the stock in the prior year. On this page, you will find recent studies that several equity research analysts have published on the company’s shares. You will be able to read these reports. In a research note published on Monday, August 15th, Piper Sandler announced that they were increasing their price objective for shares of Gamida Cell from $6.00 to $8.00. In a research report released on Thursday, June 2nd, JMP Securities reaffirmed their “buy” rating on shares of Gamida Cell and set their price objective for the company’s stock at $17.00. This information was presented in conjunction with the publication of the report. In recent months, several institutional investors and hedge funds have altered how they are invested in the company. These investors include pension funds and endowments.
During the first three months of this year, Bank of America Corporation DE saw a growth of 539.0% in its Gamida Cell holdings. After making an additional acquisition of 12,833 shares over the previous three months, Bank of America Corp DE now possesses 15,214 shares in the company. These shares are valued at $63,000 and makeup Bank of America Corp DE’s ownership stake in the company. In the second quarter, Virtu Financial LLC shelled out $36,000 to acquire a further stake in Gamida Cell. During the second quarter, Cubist Systematic Strategies LLC secured new investments in Gamida Cell. The total value of this transaction was $42,000. The purchase of new investment in the company Gamida Cell by OLD National Bancorp IN cost $57,000 during the fiscal year’s second quarter. In addition, during the final three months of 2018, GSA Capital Partners LLP acquired an additional share in Gamida Cell by paying $83,000. Institutional investors and hedge funds currently own 41.27% of the company’s shares. The GMDA stock market started the week at $2.65 per share when it opened on Monday.
The current price of Gamida Cell is $4.72, which is higher than the one-year high of $1.48 but lower than the one-year low of $4.72. The company has a current ratio of 2.57, a quick ratio of 2.57, and a debt-to-equity ratio of 9.15. The quick ratio is the same as the current ratio. The share price of the company’s stock has averaged $2.33 over the past 50 trading days and $2.70 over the last 200 trading days. The company has a price-to-earnings ratio of -2.01, and its beta value is 1.45. The market capitalization of the company is presently lying at $156.88 million. Gamida Cell (NASDAQ: GMDA) most recently revealed the results of its most recent quarterly earnings report on Monday, August 15th. The information was for the most recent quarter ending in June. The average forecast for the quarter’s earnings per share (EPS) was $0.31, while the company’s actual EPS was the same.
The company reported $0.42 per share earnings for the same quarter in the preceding year’s financial statements (negative). Sell-side analysts project that Gamida Cell will have earnings per share (EPS) of -1.25 for the current fiscal year. This projection is based on historical data. Clinical-stage biopharmaceutical startup Gamida Cell Ltd. is trying to develop cell therapies for treating life-threatening hematologic illnesses and blood malignancies. These diseases include leukemia and multiple myeloma. The principal product candidate for the firm is omidubicel, a cell therapy that has ended Phase III clinical studies in patients with high-risk hematologic malignancies and is currently in Phase I/II clinical trials in patients with severe aplastic anemia. These investigations were carried out on patients with hematologic cancers associated with a high risk of progression.